- kalina
- 16 Apr, 2003
- New York City
Pharmaceutical bellwether Eli Lilly faced a considerable drop in revenue after the patent expiry of Prozac, but its healthy pipeline could more than offset this loss.
- vanya
- 07 Apr, 2003
- New York City
Smart investors have realised that even in times of economic and geopolitical uncertainty, some education industry players offer profits and growth that are hard to find elsewhere.
- kalina
- 02 Apr, 2003
- New York City
Even as research efforts of most biotechs are stumbling along without success, Celgene has actually widened its cancer-research program and is fast cruising towards profitability.
- vanya
- 25 Mar, 2003
- New York City
At a time when the war on Iraq is driving stock markets, Weight Watchers is gaining on another one - the war on fat - as Americans spend billions on weight-loss programs & products.
- kalina
- 17 Mar, 2003
- New York City
The growing number of deals in the biotech arena suggests sector consolidation is finally under way. The FDA's recent publication of a key report is also becoming a major catalyst.
- vanya
- 09 Mar, 2003
- New York City
Even though several IT markets are declining, investors can still find growth opportunities in the security sector - particularly, in the firewall/VPN segment.
- kalina
- 03 Mar, 2003
- New York City
The shaky economy has pushed all stocks, including biotechs, to face tough times. Yet, IDEC Pharmaceuticals is one company worth betting on in this highly volatile sector.
- vanya
- 24 Feb, 2003
- New York City
As spam - or unsolicited e-mail - continues to plague corporate networks, the army of vendors offering defences is growing as well. Will fighting spam become big business?
- kalina
- 16 Feb, 2003
- New York City
Despite the many uncertainties associated with the biotech sector, there are several worthy investment choices. Biogen, which got two regulatory approvals lately, is one of them.
- vanya
- 10 Feb, 2003
- New York City
Last year was a sobering one for venture capitalists as investment activity finished at a pace that was the slowest in nearly five years. Will 2003 be better for the VC business?
- kalina
- 03 Feb, 2003
- New York City
Having managed to grow even during an economic slowdown, healthcare and pharma industry top dog Johnson & Johnson, is poised to attain greater heights in the long run.
- vanya
- 27 Jan, 2003
- New York City
Investors have become skittish about software makers, but it might be smart to keep an eye on business intelligence
- kalina
- 20 Jan, 2003
- New York City
The JP Morgan Healthcare meet did little to boost sector stocks, which were already negatively impacted by a slew of bad news. But the market climate is likely to get better soon.
- vanya
- 14 Jan, 2003
- New York City
Nanotechnology has recently emerged as one of the most hotly debated topics around the globe. But, is the
- kalina
- 09 Jan, 2003
- New York City
After a dismal 2001, biotech stocks ended 2002 on a much weaker note. Still, industry fundamentals seem to be improving and some stocks may give patient investors reasons to cheer